Recurrence in Breast Cancer Patients With Negative Sentinel Lymph Node Biopsy
abstract
This abstract is available on the publisher's site.
Access this abstract now Full Text Available for ClinicalKey SubscribersIntroduction
The objective of our study was to assess recurrence after negative sentinel node biopsy (NSNB) and to determine risk factors related to local and distant recurrence in this group of patients.
Methods
This is a prospective observational study conducted from 2006 to 2011. It included 607 patients with breast cancer in early stages and NSNB, with a 5-year follow up.
Results
Disease-free survival rate was 98.5% and 96.5% at 2 and 5 years respectively. Multivariate analysis identified disease recurrence prognosis factors: tumour necrosis (HR 4.89, 95%CI 1.61-14.89, p=0.005), lymphatic vascular invasion (HR 3.46, 95%CI 1.14-10.55, p=0.029), T2 tumour size (HR 4.35, 95%CI 1.40-13.52, p=0.011) and moderate/severe lymphoplasmacytic stromal infiltration (HR 3.06, 95%CI 1.18-7.96, p=0.022).
Conclusion
Recurrence results in patients with NSNB are satisfactorily low. Nevertheless, prognosis factors related to a higher recurrence rate could help to identify high-risk patients and influence on systemic adjuvant therapeutic management.
Click on any of these tags to subscribe to Topic Alerts. Once subscribed, you can get a single, daily email any time PracticeUpdate publishes content on the topics that interest you.
Visit your Preferences and Settings section to Manage All Topic Alerts